about
Malaria: prevention in travellersAdverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement?Idiosyncratic adverse drug reactions: current conceptsTolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, LiberiaMalaria: prevention in travellers.Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi.Amodiaquine-associated adverse effects after inadvertent overdose and after a standard therapeutic dose.Extracts from "Clinical Evidence". Malaria: prevention in travellers.Science, medicine and clinical pharmacology. The Lilly Lecture 1994.The disposition of amodiaquine in Zambians and Nigerians with malaria.Idiosyncratic drug reactions: a mechanistic evaluation of risk factorsJPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium.Fixed dose artesunate amodiaquine - a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine.Disposition of amopyroquin in rats and rabbits and in vitro activity against Plasmodium falciparum.Antimalarial agents: specific chemoprophylaxis regimens.Comparison of mosquito nets, proguanil hydrochloride, and placebo to prevent malaria.Discovery of New Classes of Compounds that Reactivate Acetylcholinesterase Inhibited by OrganophosphatesReview of pyronaridine anti-malarial properties and product characteristics.Anti-malarial drug safety information obtained through routine monitoring in a rural district of South-Western SenegalMalaria chemoprophylaxis among European tourists in tropical Africa: use, adverse reactions, and efficacyAscertainment of risk of serious adverse reactions associated with chemoprophylactic antimalarial drugsMalaria in the liver.Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers.Effect of monodesethyl amodiaquine on human polymorphonuclear neutrophil functions in vitro.Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up.A quantitative approach to recommendations on malaria prophylaxis.Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria.The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparumAmodiaquine dosage and tolerability for intermittent preventive treatment to prevent malaria in children.Hydroxychloroquine-induced agranulocytosis in a patient with long-term rheumatoid arthritis.Effect of disposition of mannich antimalarial agents on their pharmacology and toxicology.New quinoline di-Mannich base compounds with greater antimalarial activity than chloroquine, amodiaquine, or pyronaridine.Synergism between amodiaquine and its major metabolite, desethylamodiaquine, against Plasmodium falciparum in vitro.The disposition of amodiaquine in man after oral administration.The toxicity of amodiaquine and its principal metabolites towards mononuclear leucocytes and granulocyte/monocyte colony forming units.Characterization of human cytochrome P450 mediated bioactivation of amodiaquine and its major metabolite N-desethylamodiaquine.Recent updates in the discovery and development of novel antimalarial drug candidatesDevelopment of recommendations for the protection of short-stay travellers to malaria endemic areas: Memorandum from two WHO MeetingsRepurposing antimalarial aminoquinolines and related compounds for treatment of retinal neovascularization
P2860
Q24627214-F8DF5DCD-1119-4B23-8468-F75F34B9EB07Q24806081-645C44D2-352C-4422-80D9-DB4196B4EEA1Q26824391-0134D954-656E-4579-B41A-C0A4A94B182CQ28691509-0643FA42-C0FE-45B6-B8E6-D33A7E222338Q30479499-E162429A-A57A-42F1-A0D0-02476E32F6FFQ33319559-B9DB9922-D538-46E8-AF79-000B9904E8C6Q33605669-726F77AA-D930-48F2-B198-56A9D6159ACCQ33801237-EF3DFBDF-DC32-437B-824D-716322046D59Q34347099-1C660970-69CF-4108-8F3F-DD7E5DFECEF6Q34398501-577728A3-C1CF-4341-9CA4-73D34250CF04Q34403403-0A9B4EE5-7D0E-4ACC-AB63-902789045306Q34922167-09D3FA91-48E8-432A-9D72-EEFADA3C2FA3Q34996451-18A10305-0C6F-4654-B6CF-933D5DCF302AQ35300502-29C98F9A-F26B-42DF-971C-D2410B1FC7A2Q35311711-C5F8A00B-0A13-4C61-8E71-F4C9473DC88CQ35702833-7829EFC5-B9F1-40B1-9261-62AC46955818Q36331614-611973F0-1CA4-4455-94CE-05457863D263Q36353708-CBE70190-B190-4DDF-B10C-660BA03AA891Q36544502-B6511A30-7812-4096-B85C-FB78002251D9Q36668633-B18C76C2-76FB-4A4D-BE0C-C4F3C0AF0F5BQ36668853-885A9859-9061-42C9-91AB-5EE807325E5EQ36679388-32C8C4ED-9378-48F1-8C93-0EDDFECAA2F9Q36718308-9ADECEB3-48D6-4086-8086-6FC298E1E026Q36753650-7351D4CD-0923-4CBC-975B-04F190CA66EFQ36782415-22FFACB6-5115-4CA2-B7D7-1054DB6F3463Q36799700-8F197960-FEE2-4794-BE48-2EDF0DFE825FQ36993430-C89CC694-C244-48D4-B0DF-AD669D425C52Q37144195-25699312-B399-4027-9682-9B3774FE06D4Q38928995-C4BD44C0-EF57-4424-8340-BA198941D93BQ38973265-C747236C-16F6-47DB-88A9-89B8D59EDAF7Q39558835-838FBD99-B193-47AA-8C5F-6F91BA0939DBQ39784386-9870F7CA-8397-4E87-90BE-2B3C07CFC6E4Q40291075-DF807620-8DF7-4740-99B4-07B420F4BA71Q41914279-67C73F48-BD14-4EAD-A24F-087B3A379FB3Q41944054-1D44BF16-0B2A-416C-B857-110D74CC370CQ51414867-5C4DB7FB-ED5A-45BC-97E5-34F0AF190E00Q56403247-22492D3B-19E7-4E8B-9FE7-4934F65625A1Q57951547-ECA26FF9-D03F-464E-AE4E-7FAD83D84345Q58747914-47F093AA-5107-48E1-98C1-6EAD4B5E0FE3
P2860
description
1986 nî lūn-bûn
@nan
1986 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի մարտին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
Amodiaquine induced agranulocytosis and liver damage.
@ast
Amodiaquine induced agranulocytosis and liver damage.
@en
Amodiaquine induced agranulocytosis and liver damage.
@nl
type
label
Amodiaquine induced agranulocytosis and liver damage.
@ast
Amodiaquine induced agranulocytosis and liver damage.
@en
Amodiaquine induced agranulocytosis and liver damage.
@nl
prefLabel
Amodiaquine induced agranulocytosis and liver damage.
@ast
Amodiaquine induced agranulocytosis and liver damage.
@en
Amodiaquine induced agranulocytosis and liver damage.
@nl
P2093
P2860
P356
P1433
P1476
Amodiaquine induced agranulocytosis and liver damage
@en
P2093
P2860
P304
P356
10.1136/BMJ.292.6522.721
P407
P577
1986-03-01T00:00:00Z